GlassScriptPhysician profile
Alexa R Stecker
NPI 1073969051
$11,050.24
in general payments reported to CMS, 2019-2025
33 companies · $3,072 in 2025
The $3,072 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $230 · 2021: $981 · 2022: $1,795 · 2023: $1,673 · 2024: $3,299 · 2025: $3,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,579 · Education: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,579.38 |
| Education | $464.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,315.44 | 2020-2025 | |
| Lilly USA, LLC | $1,290.21 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $1,246.30 | 2020-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $950.83 | 2021-2025 | |
| Incyte Corporation | $793.12 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $639.31 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $523.61 | 2021-2025 | Dupixent, Libtayo |
| Revance Therapeutics, INC. | $493.63 | 2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $455.70 | 2022-2025 | Absorica Ld, Winlevi, Ilumya |
| Pfizer INC. | $437.26 | 2021-2025 | |
| Ucb, INC. | $408.74 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $353.19 | 2022-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $279.57 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $270.00 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $248.66 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $230.87 | 2020-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $201.47 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $195.92 | 2021-2025 | Jublia, Arazlo, Duobrii |
| Novartis Pharmaceuticals Corporation | $174.77 | 2021-2025 | |
| Biofrontera INC. | $86.50 | 2025 | |
| Galderma Laboratories, L.P. | $82.70 | 2020-2024 | Aklief |
| Organon LLC | $78.96 | 2025 | Vtama |
| Almirall LLC | $41.15 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $38.50 | 2023 | |
| Convatec INC. | $38.10 | 2024 | |
| Arcutis Biotherapeutics, INC. | $37.60 | 2024 | Zoryve |
| Nabriva Therapeutics, Plc | $29.22 | 2022 | |
| Dermira, INC. | $26.63 | 2020 | |
| Journey Medical Corporation | $17.94 | 2021 | |
| Verrica Pharmaceuticals INC. | $17.62 | 2024 | Ycanth |
| Botanix Sb INC | $17.37 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $15.36 | 2021 | |
| Epi Health, LLC | $13.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Stecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.